Evidence map›Paper›PMID 40405106›Full record

ArticleBMC public health2025

Incidence and risk factors for tuberculosis at a rural HIV clinic in Uganda, 2012-2019; A retrospective cohort study.

Ibrahim Sendagire, Victor Ssempijja, Anthony Ndyanabo, Absalom Ssettuba, Annie N Mawanda, Gertrude Nakigozi, Deus Lukoye, Arthur G Fitzmaurice, Richard Muhindo, Stella Zawedde-Muyanja and 1 more

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ibrahim SendagireDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Kampala, Uganda. isendagire@rhsp.org.
Victor SsempijjaRakai Health Sciences Program, Kalisizo, Kyotera, Uganda.
Anthony NdyanaboRakai Health Sciences Program, Kalisizo, Kyotera, Uganda.
Absalom SsettubaRakai Health Sciences Program, Kalisizo, Kyotera, Uganda.
Annie N MawandaRakai Health Sciences Program, Kalisizo, Kyotera, Uganda.
Gertrude NakigoziRakai Health Sciences Program, Kalisizo, Kyotera, Uganda.
Deus LukoyeDivision of Global HIV & TB, Global Health Center, US Centers for Disease Control and Prevention, Kampala, Uganda.
Arthur G FitzmauriceDivision of Global HIV & TB, Global Health Center, US Centers for Disease Control and Prevention, Kampala, Uganda.
Richard MuhindoDepartment of Nursing, Makerere College of Health Sciences, Kampala, Uganda.
Stella Zawedde-MuyanjaInfectious Diseases Institute, Makerere College of Health Sciences, Kampala, Uganda.
Steven J ReynoldsDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.

Funding

HIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.D43TW009771 · FIC · JOHNS HOPKINS UNIVERSITY · PI CASTELNUOVO, BARBARA, KAMBUGU, ANDREW DDUNGU · 2014 to 2023
$3.3M
FIC NIH HHS D43 TW009771National Institute of Allergy and Infectious Diseases, NIH AI 1001040President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Centers for Disease Control and Prevention NU2GGH002009 and NU2GGH000817
6 · The paper itself

Abstract

backgroundTuberculosis (TB) is the leading cause of death among people living with HIV (PLHIV). Antiretroviral therapy (ART) initiation lowers the risk of HIV-associated TB. Earlier studies have shown TB incidence to be high in the first year of ART. We undertook a study to (1) assess the incidence of TB and (2) associated factors among persons initiating ART in a rural cohort.

methodsWe conducted a retrospective cohort analysis study among PLHIV aged ≥ 18 years, initiated on ART from January 1, 2012, to December 31, 2019, and TB disease-free at the time of ART initiation, at Kalisizo ART clinic. TB disease incidence was calculated by dividing the number of new TB cases by the total follow-up time expressed per 100 person-years among persons followed up until the date of incident TB disease, loss to follow-up, transfer out, death or censored at the end of the study; whichever occurred first. Factors associated with TB disease incidence were assessed in the multivariable analysis by Poisson regression analysis at 5% significance level.

resultsFor the period 2012 to 2019, 2,589 PLHIV were initiated on ART; 57% (1,470/2,589) were female. Females were more likely to be aged below 35 years while males were more likely to be aged 25-44 years (p < 0.001). Eighty-seven per cent (1,269/1,470) of females compared to 78% (866/1,119) of males were in WHO clinical stage 1 (p < 0.001). Sixty-one TB disease events were observed in 7,363 person-years. The overall TB disease incidence was 0.83 (95% CI: 0.63-1.06) per 100 person-years. Males were more likely than females to develop TB disease, adjusted incidence rate ratio (adj IRR) 2.13 (95% CI: 1.27-3.57) per 100 person-years, p = 0.004. Compared to using ART for 0-5 months, time on ART was associated with a lower TB incidence rate at 6-12 months, 13-24 months, > 24 months (adj IRR 0.20 (95% CI: 0.09-0.46), 0.14 (95% CI: 0.06-0.33), 0.16 (95% CI: 0.08-0.31) p < 0.001 respectively). CONCLUSIONS AND RECOMMENDATIONS: Incidence of TB among PLHIV on ART was low in this rural population. Clinicians offering care to people with HIV in the rural setting should have a heightened index of suspicion for TB disease.

Indexed as

HIV InfectionsRural PopulationTuberculosisAdolescentAdultFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsUgandaYoung AdultAfricaTBTB/HIV prevalenceTB incidence during ARTTuberculosisTuberculosis in HIV patientsTuberculosis in rural areas

Identifiers

PMID40405106
PMCPMC12096586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.